| dc.contributor.author | Tugal-Tutkun, Ilknur | |
| dc.contributor.author | Gül, Ahmet | |
| dc.contributor.author | PAVESIO, Carlos | |
| dc.contributor.author | BERNARD-POENARU, Oana | |
| dc.contributor.author | DE CORDOUE, Agnes | |
| dc.date.accessioned | 2021-03-02T21:33:29Z | |
| dc.date.available | 2021-03-02T21:33:29Z | |
| dc.date.issued | 2018 | |
| dc.identifier.citation | Tugal-Tutkun I., PAVESIO C., DE CORDOUE A., BERNARD-POENARU O., Gül A., "Use of Gevokizumab in Patients with Behcet's Disease Uveitis: An International, Randomized, Double-Masked, Placebo-Controlled Study and Open-Label Extension Study", OCULAR IMMUNOLOGY AND INFLAMMATION, cilt.26, sa.7, ss.1023-1033, 2018 | |
| dc.identifier.issn | 0927-3948 | |
| dc.identifier.other | vv_1032021 | |
| dc.identifier.other | av_07a0cef3-1d94-4e17-9557-5a638732620d | |
| dc.identifier.uri | http://hdl.handle.net/20.500.12627/10956 | |
| dc.identifier.uri | https://doi.org/10.1080/09273948.2017.1421233 | |
| dc.description.abstract | Purpose: The purpose of this article is to demonstrate the superiority of gevokizumab as compared to placebo, on top of current standard of care, in reducing the risk of Behcet's disease uveitis (BDU) exacerbations. | |
| dc.language.iso | eng | |
| dc.subject | OFTALMOLOJİ | |
| dc.subject | Göz Hastalıkları ve Cerrahisi | |
| dc.subject | Cerrahi Tıp Bilimleri | |
| dc.subject | Sağlık Bilimleri | |
| dc.subject | Tıp | |
| dc.subject | Klinik Tıp (MED) | |
| dc.subject | Klinik Tıp | |
| dc.title | Use of Gevokizumab in Patients with Behcet's Disease Uveitis: An International, Randomized, Double-Masked, Placebo-Controlled Study and Open-Label Extension Study | |
| dc.type | Makale | |
| dc.relation.journal | OCULAR IMMUNOLOGY AND INFLAMMATION | |
| dc.contributor.department | , , | |
| dc.identifier.volume | 26 | |
| dc.identifier.issue | 7 | |
| dc.identifier.startpage | 1023 | |
| dc.identifier.endpage | 1033 | |
| dc.contributor.firstauthorID | 51169 | |
